Health Insurance (Botulinum Toxin for Urinary Incontinence due to Neurogenic Detrusor Overactivity) Determination 2013

Link to law: https://www.comlaw.gov.au/Details/F2013L01726

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
Health Insurance (Botulinum Toxin for Urinary Incontinence due to Neurogenic Detrusor Overactivity) Determination 2013
Health Insurance Act 1973
I, RICHARD BARTLETT, First Assistant Secretary, Medical Benefits Division, Department of Health and Ageing, make this Determination under subsection 3C (1) of the Health Insurance Act 1973.
Dated                                16  September 2013
RICHARD BARTLETT
First Assistant Secretary
Medical Benefits Division
Department of Health and Ageing
Contents
1                   Name of determination  3
2                   Commencement 3
3                   Cessation  3
4                   Authority  3
5                   Interpretation  3
6                   Treatment of a relevant service  3
7                   Application of specified provisions of the general medical services table  3
Schedule 1         Specified Health Services  4
 
1        Name of determination
This determination is the Health Insurance (Botulinum Toxin for Urinary Incontinence due to Neurogenic Detrusor Overactivity) Determination 2013 .
2        Commencement
This determination commences on 1 October 2013.
3        Cessation
This determination ceases as if repealed at midnight 31 October 2013.
4        Authority
This determination is made under the Health Insurance Act 1973.
5        Interpretation
(1)   In this determination:
Act means the Health Insurance Act 1973.
relevant provisions means all provisions of the Act and regulations made under the Act and the National Health Act 1953 and all regulations under that Act, relating to professional services, medical services or items.
relevant service means a health service specified in an item in the Schedule to this determination.
6        Treatment of a relevant service
A relevant service provided in accordance with this determination is to be treated, for the relevant provisions, as if:
(a)                        it were both a professional service and a medical service; and
(b)                       there were an item in Group T11 of the general medical services table that:
i.           related to the service; and
ii.         specified for the service a fee in relation to each State, being the fee specified in the Schedule in relation to the service.
7        Application of specified provisions of the general medical services table
(1)        The following provisions of the general medical services table shall have effect as if item 18375 were also specified in that provision:
(a)      clause 1.2.1;
(b)     subclauses 1.2.4(1);
(c)      subclause 1.2.5(1);
(d)     subclauses 2.42A.1(1) and 2.42A.1(2).  
Schedule 1        Specified Health Services
 
Item
Health Service
Fee for all States

18375
 
Botulinum toxin type A (Botox), intravesical injection of, with cystoscopy, for the treatment of urinary incontinence, including all such injections on any one day, if:
 
(a) the urinary incontinence is due to neurogenic detrusor overactivity as demonstrated by urodynamic study of a patient with:
(i) multiple sclerosis; or
(ii) spinal cord injury; or
(iii) spina bifida and who is at least 18 years of age; and
(b) the patient has urinary incontinence that is inadequately controlled by anti-cholinergic therapy, as manifested by having experienced at least 14 episodes of urinary incontinence per week before commencement of treatment with botulinum toxin type A; and
(c) the patient is willing and able to self-catheterise; and
(d) the requirements relating to botulinum toxin type A under the Pharmaceutical Benefits Scheme are complied with; and
(e) treatment is not provided on the same occasion as a service described in item 104, 105, 110, 116, 119, 11900 or 11919.
 
For each patient—applicable not more than once except if the patient achieves at least a 50% reduction in urinary incontinence episodes from baseline at any time during the period of 6 to 12 weeks after first treatment
(H) (Anaes.)
$229.85